|
⚲
|
| Keyboard |
| Atrium Therapeutics Inc
✚
|
|
|---|---|
| CIK # | 0002093101 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 10-Q | [0002093101] | |
| 3 | [0002093101] | |
| 4 | [0002093101] | |
| 8-K | [0002093101] | |
| SC 13G | [0002093101] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| RA Capital Management LP | Atrium Therapeutics Inc | [2026-05-15] |
| BlackRock Inc | Atrium Therapeutics Inc | [2026-04-27] |
| Price T Rowe Associates Inc /MD/ | Atrium Therapeutics Inc | [2026-04-08] |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Atrium Therapeutics Inc RNA
Stock Option (Right to Buy) · derivative
|
2026-02-27 | Grant | 20,000 | $0.00 | |
|
Atrium Therapeutics Inc RNA
Stock Option (Right to Buy) · derivative
|
2026-02-27 | Grant | 20,000 | $0.00 | |
|
Atrium Therapeutics Inc RNA
Stock Option (Right to Buy) · derivative
|
2026-02-27 | Grant | 20,000 | $0.00 | |
|
Atrium Therapeutics Inc RNA
Stock Option (Right to Buy) · derivative
|
2026-02-27 | Grant | 20,000 | $0.00 | |
|
Atrium Therapeutics Inc RNA
Stock Option (Right to Buy) · derivative
|
2026-02-27 | Grant | 20,000 | $0.00 |